A detailed history of Jpmorgan Chase & CO transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 904 shares of CUE stock, worth $1,346. This represents 0.0% of its overall portfolio holdings.

Number of Shares
904
Previous 15,426 94.14%
Holding current value
$1,346
Previous $29,000 96.55%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$1.24 - $2.18 $18,007 - $31,657
-14,522 Reduced 94.14%
904 $1,000
Q1 2024

May 10, 2024

SELL
$1.77 - $3.09 $12,416 - $21,676
-7,015 Reduced 31.26%
15,426 $29,000
Q3 2023

Nov 14, 2023

SELL
$2.23 - $4.69 $11,462 - $24,106
-5,140 Reduced 18.64%
22,441 $51,000
Q2 2023

Aug 11, 2023

BUY
$3.11 - $4.91 $85,655 - $135,231
27,542 Added 70620.51%
27,581 $100,000
Q2 2022

Aug 11, 2022

SELL
$2.49 - $5.92 $36,234 - $86,147
-14,552 Reduced 99.73%
39 $0
Q1 2022

May 11, 2022

BUY
$4.41 - $12.28 $11,227 - $31,264
2,546 Added 21.14%
14,591 $71,000
Q4 2021

Feb 10, 2022

BUY
$10.86 - $17.85 $5,538 - $9,103
510 Added 4.42%
12,045 $136,000
Q3 2021

Nov 12, 2021

BUY
$10.06 - $15.3 $116,042 - $176,485
11,535 New
11,535 $168,000

Others Institutions Holding CUE

About Cue Biopharma, Inc.


  • Ticker CUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,381,700
  • Market Cap $52.7M
  • Description
  • Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...
More about CUE
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.